health

The most complete story of May is the gut-brain axis, which moved from lifestyle advice to clinical intervention over four weeks. It opened with a randomized trial showing that Mediterranean diet counselling meaningfully relieved constipation — one of the most underaddressed non-motor symptoms — and a prebiotic supplement study that both restored healthier gut bacteria and established a blood test to track gut-brain communication over time. It culminated with the first published human safety and efficacy data for faecal microbiota transplantation (FMT) — a procedure that replaces the patient's entire gut bacterial community with a healthy donor's. FMT is not standard care and remains in specialist trials, but the field's central question has shifted: not "might the gut matter?" but "how far can we push gut intervention?" For everyone short of a trial slot, Mediterranean diet and prebiotic supplementation are worth raising at the next neurology appointment. Evidence: preprint dietary RCT; early interventional (prebiotic); first human safety/efficacy (FMT).

Gene therapy clears its first human hurdle

The most structurally significant shift for long-term disease modification is the publication of Phase 1/2 data for OXB-102 (Axo-Lenti-PD), a viral vector gene therapy that delivers dopamine synthesis genes directly into the striatum — aiming to rebuild the brain's own production machinery rather than replacing the signal from outside. Safety signals were acceptable and early motor effects were observed. This is a small open-label trial with no control arm, so the efficacy signal is exploratory. But gene therapy for Parkinson's has now cleared the first real human hurdle. Nothing to act on today; worth tracking if you are following disease-modification options.

The largest disease-modification bet of the decade fails

In direct contrast, Biogen and Denali halted the BIIB122 trial — one of the most-watched and best-funded LRRK2 inhibitor studies in idiopathic (non-genetic) Parkinson's — after the drug failed to slow progression. LRRK2 inhibition had been a leading disease-modification hypothesis for the general PD population. This result closes that chapter for people without a confirmed LRRK2 gene variant; it does not rule out LRRK2 as a target in variant carriers, but it recalibrates expectations for near-term disease modification in the broader population.

A precision prognosis toolkit is assembling

Three threads this month converge on the question patients ask most: what will my disease look like, and when? A large Annals of Neurology study established that levodopa responsiveness — how well a patient responds to the main Parkinson's drug — is not just a therapeutic variable but a diagnostic and prognostic signal tied to underlying brain pathology, useful for distinguishing PD from related conditions like MSA (multiple system atrophy) and PSP (progressive supranuclear palsy). The alpha-synuclein seed amplification assay (SAA) — a blood or CSF test detecting misfolded protein — now identifies which carriers of the LRRK2 gene variant already have active PD pathology. And the largest genetic analysis of cognitive decline yet, a 15-year meta-analysis across 24 cohorts, shows that cumulative genetic risk score — not any single gene — shapes cognitive trajectory. None of these tools yet routinely drive treatment decisions, but they inform prognosis conversations and trial eligibility. If cognitive trajectory concerns you, ask your neurologist whether genetic counselling is appropriate; if you are in a genetic monitoring program, ask whether SAA testing has been done. Free genetic testing through the now-international PD GENEration program is an accessible starting point. Evidence: large observational cohorts; one preprint (SAA/LRRK2).

Loneliness is a disease modifier — with pathological backing

A longitudinal community-based study, unusually confirmed against brain tissue at autopsy, found that loneliness independently predicts faster motor worsening in Parkinson's. The pathological anchoring lifts this above the usual social-determinants literature. For caregivers: reducing a patient's social isolation has the same clinical standing as medication adherence or exercise. Evidence: observational longitudinal, pathologically confirmed.

Wearables: the evidence base is now strong enough to ask about

Two studies closed a persistent gap between laboratory performance and real-world utility. Cross-country wearable validation and a finding that sensor-derived tremor measures detect early progression together mean that wearable monitoring now has rigorous observational backing across health systems. Not yet standard of care, but if clinic visits are infrequent and you are in early-stage PD, the evidence now supports asking whether a validated wearable is available. Evidence: rigorous observational validation.

Practical gains worth acting on now

Several smaller threads are worth acting on rather than watching. Safinamide — already used for motor fluctuations — produced marked improvement in drooling (sialorrhea) in a case series; if drooling is a daily burden and safinamide is already on your regimen or under consideration, raise it explicitly. Head-up tilt sleeping — tilting the entire bed frame slightly — showed tolerability and autonomic benefit for people with overnight blood pressure instability or marked early-morning stiffness; testable at minimal cost. With summer underway in the northern hemisphere, high temperatures can worsen both motor and non-motor symptoms, slow medication absorption, and raise fall risk — plan outdoor activities during cooler hours and maintain hydration vigilantly during heatwaves. Evidence: case series (safinamide); small clinical study (tilt); expert/clinical experience (heat).

Pipeline: one trial completes, one to watch

The Celeste pivotal trial for a light therapy device completed enrollment; results are now expected for this drug-free approach with existing positive signals for sleep and mood. The Phase 3 solengepras trial — a non-dopaminergic mechanism, meaning it works through a pathway other than replacing lost dopamine — is fully enrolled, putting results within a foreseeable horizon. Neither changes today's options, but both are worth tracking.